Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Apimeds Pharmaceuticals US, Inc. ( (APUS) ) has provided an update.
On November 13, 2025, Apimeds Pharmaceuticals US, Inc. amended its Executive Employment Agreement with CEO Erik Emerson, increasing his annual base salary to $500,000. The amendment also outlines severance terms, including a payment equivalent to 24 months of salary and benefits if terminated without cause, and immediate vesting of unvested equity, impacting the company’s executive compensation structure and potentially influencing stakeholder perceptions.
More about Apimeds Pharmaceuticals US, Inc.
Average Trading Volume: 105,571
Technical Sentiment Signal: Strong Buy
Current Market Cap: $40.37M
For an in-depth examination of APUS stock, go to TipRanks’ Overview page.